Receive Our Newsletter

Hemophilia Bleeding Disorder Industry News
Industry News

Biogen Idec Forms Partnership to Focus on Gene Therapy for Hemophilia

Biogen Idec, Fondazione Telethon, and Ospedale San Raffaele have entered into a worldwide collaboration to jointly develop gene therapies for the treatment of both hemophilia A and B. The agreement will combine San Raffaele – Telethon Institute for Gene Therapy’s (TIGET) extensive expertise in creating new gene therapy strategies and developing them from the bench to bedside […]

Industry News

Bayer’s Hemophilia Leadership Application Closes 3/13

The Bayer Hemophilia Leadership Development Program was created by Bayer — with hemophilia advocacy organizations, healthcare professional thought leaders, and other community advocates — to help prepare future leaders in the hemophilia community. For years, Bayer has offered motivated, young individuals who are touched by hemophilia a paid internship at Bayer’s U.S. headquarters in New […]

industry_news_fb

Baxter Files For FDA Approval of Recombinant Treatment For von Willebrand Disease

Baxter International Inc. today announced that the company has submitted a biologics license application (BLA) to the United States (U.S.) Food and Drug Administration (FDA) for the approval of BAX111, the first highly-purified recombinant von Willebrand Factor (rVWF) in clinical development as a treatment for patients with von Willebrand disease, the most common type of […]

industry_news_fb

CSL Behring Submits FDA Approval for Long Acting Hemophilia B Product

CSL Behring announced on Tuesday, December 16, 2014 that it has submitted a biologics license application (BLA) to the United States Food and Drug Administration (FDA) for the marketing authorization of its long-acting fusion protein linking recombinant coagulation factor IX with recombinant albumin (rIX-FP). Once approved by the FDA, rIX-FP (Coagulation Factor IX {Recombinant}, Albumin […]

industry_news_fb

Pfizer Establishes Gene Therapy Partnership

Pfizer Inc. announced on Monday, December 8, 2014  two strategic decisions to expand the company’s rare disease research and development activities through the establishment of a gene therapy platform to investigate potential treatments for patients. First is an agreement with Spark Therapeutics to develop SPK-FIX, a program incorporating a bio-engineered AAV vector for the potential […]

industry_news_fb

Baxter Seeks OK to Sell New Hemophilia Drug

Baxter International submitted an application to the Food and Drug Administration for the approval of a key hemophilia drug. The drug, BAX 855, is an extended-release version of its flagship hemophilia drug Advate, which is sold in dozens of countries. The treatment is seen as a key part of the company’s drug pipeline and its […]

Industry News

CSL Behring Announces 2014 Gettin’ in the Game Winners

CSL Behring’s Gettin’ in the Game program, like our FitFactor program, encourages patients with hemophilia, von Willebrand disease (vWD), and other bleeding disorders to become active and stay active, touting the physical and mental benefits of sports and other activities. Recently, CSL Behring held their 13th Junior National Championship program, an annual golf and baseball […]

Industry News

PPTA: Ebola Virus and Plasma Protein Therapies

The recent outbreak of Ebola virus has caused great concern among many people. We read stories about isolation, experimental therapies and many deaths. It is understandable that this raises questions for persons who are more vulnerable to infections such as persons with immunedeficencies. We have seen questions and concerns expressed by various persons and would […]

Industry News

Biogen and MicroHealth Launch Digital Health App

Micro8 is a secure application that may help the Hemophilia A community manage infusion schedules and track bleeding episodes, and may help clinicians stay updated on their patients’ care. Micro8 provides mobile app, text- messaging and web-based tracking options for individuals and caregivers, who have historically logged infusions and bleeding episodes on paper or have […]

Industry News

Grifols Launches Higher Potency Alphanate

Grifols, a leader in the production of plasma-derived medicines, announces the launch of a 2000 IU/vial assay size for ALPHANATE. ALPHANATE is indicated for the control and prevention of bleeding in patients with Hemophilia A and for surgical and/or invasive procedures in adult and pediatric patients with von Willebrand disease in whom desmopressin (DDAVP) is […]

Page 5 of 1812345678910NextLast »

Assisting and Advocating for the Bleeding Disorders Community